Lexicon's LX5171

LX5171: "Thursday, Lexicon Genetics Inc. (a pharmaceutical utility of genes, said it filed a clinical trial authorization for LX6171 with the United Kingdom Medicines and healthcare products regulatory agency or MHRA. The company disclosed that the LX6171 is a small molecule compound for the treatment of cognitive disorders. Lexicon said it expects to develop the LX6171 for the treatment of cognitive disorders including Alzheimer's disease, schizophrenia, vascular dementia, attention deficit disorder and fragile X syndrome."